Thus, while there is no doubt that endogenous TRAIL has a permissive role in the induction of experimental asthma [4]–[6], [27], emerging evidences [9], including our results, suggest that recombinant TRAIL administration can have a protective role in allergic airway inflammation. The gene discussed is TNFSF10; the disease is asthma.